NOVOPEN Echo Plus Insulin Pen

Product Information

Results from an observational study indicate that using NovoPen® 6 to administer their insulin could give people living with type 1 diabetes close to two extra hours of improved glucose levels (measured as HbA1c 3.9 – 10.0 mmol/L) per day, with a reduction in time spent in hyperglycaemia (measured as HbA1c >10 mmol/L) and level 2 hypoglycaemia (measured as HbA1c <3.0 mmol/L). The two smart connected insulin pens now allow healthcare professionals to view the insulin dosing information of people with diabetes, helping to facilitate more productive consultations and support personalised treatment guidance. Beyond reusable pens, which are more popular outside the US, Novo Nordisk also announced that connectivity for disposable pens is coming “later in 2019.” This feature will capture insulin doses through a Bluetooth-enabled smart device that is attached to the widely used disposable FlexTouch pen. The attachment will transmit the insulin dose, time of dose, and the type of insulin being injected to a phone app (an important safety precaution to avoid mix-ups). Novo Nordisk has not shared any pictures, so we’re not sure if it will include a screen and what apps it will communicate with. Still, it is exciting that Novo Nordisk will have smart connectivity for both reusable and disposable insulin pens! New Partnerships A leading global healthcare company has launched two smart connected insulin pens in the UK to improve the lives of people living with diabetes.

NovoPen® 6 | Hypodermic insulin injection pens | Medical NovoPen® 6 | Hypodermic insulin injection pens | Medical

NovoPen 6 and NovoPen Echo Plus are insulin injection pens that record dosing information, including when and how much insulin was administered. This data can be uploaded to a compatible app and viewed by people living with diabetes and their healthcare professionals. Currently, insulin injection dosing information is manually recorded in a log book or app. However, in clinical practice, incomplete or inaccurate information on insulin dosing and timing can be a significant barrier to optimising glycaemic control. Pinder Sahota, General Manager, Novo Nordisk UK, said: “We believe digital innovation of devices and treatments has the potential to transform people’s lives and help alleviate the daily burden of living with diabetes. The kid-friendly Echo Plus allows for half-unit dosing and a maximum 30-unit injection, whereas the NovoPen 6 has a minimum dose of one unit and a maximum dose of 60 units. Over time, these new connected pens will replace the NovoPen 5 and current NovoPen Echo. Attachment for Disposable Pens Novo Nordisk long-term strategy involves enhanced access to the connected pens and offering personalised treatment guidance solutions for people living with diabetes.”Novo Nordisk has signed collaboration agreements with Glooko, Roche and DexCom to support the future integration of its NovoPen 6 and NovoPen Echo Plus insulin pens with digital health solutions. Xultophy (which is insulin degludec combined with liraglutide) is available as a pre-filled pen for people with type 2 diabetes who need both medicines to manage their blood glucose. Key facts NovoPen ® 6 and NovoPen Echo ® Plus smart insulin pens collect dose data and time and date of dose to better inform the management of diabetes alongside blood glucose monitoring. pre-filled pens containing insulin degludec combined with liraglutide, for people with type 2 diabetes who need both medicines Novo Nordisk’s new NovoPen 6 and NovoPen Echo Plus are set to replace NovoPen 5 and NovoPen Echo. Credit: Novo Nordisk A/S.

Your quick guide to using NovoPen® 6 or NovoPen Echo® Plus Your quick guide to using NovoPen® 6 or NovoPen Echo® Plus

Toujeo comes as pre-filled pens. Toujeo contains 300 units of insulin per 1ml of liquid which is 3 times more concentrated than the other brands. It will allow for more tailored and informed advice on optimisation of glucose levels, with the ultimate goal of improving future outcomes.” Novo Nordisk has announced that the NovoPen® 6 and NovoPen Echo® Plus are both now available on prescription for individuals with diabetes who are treated with Novo Nordisk insulin in the UK. Glooko: In January 2017,Novo Nordisk and Glooko announced a partnershipto develop digital diabetes tools together. Since that time, they have launched the Cornerstones4Care app, and the two will continue to work together as Novo Nordisk brings its connected insulin pens to market. Earlier this year, Glooko received FDA clearance for a basal insulin dosing advice app, and we hope to see that come to market at some point.Long-acting insulin starts to work after 30 minutes to 4 hours, depending on the type. It usually lasts for 16 to 24 hours, depending on the type and your dose. You'll usually take it once or twice a day.

Smart insulin pens: How they work, and your experiences of

She added: “In my clinic, the opportunity to view daily insulin data will allow me to better support the individual with diabetes to achieve their goals.

We spoke to two members of the diabetes community to understand their experiences with smart insulin pens and explore the impact that widespread use of these pens could have on diabetes teams as well as people with diabetes. What is a smart insulin pen?